Development of hepatic veno-occlusive disease after mylotarg infusion for relapsed acute myeloid leukemia

D. K. Tack, L. Letendre, Patrick Sequeira Kamath, Ayalew Tefferi

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Mylotarg (gemtuzumab zogamicin) is a conjugated monoclonal antibody that has recently become available for use in patients with relapsing or refractory acute myeloid leukemia. Reversible hepatotoxicity is common after administration. We describe the first report of hepatic veno-occlusive disease (HVOD) developing after Mylotarg infusion in a patient who underwent hematopoietic stem cell transplantation 8 months earlier. Certain antineoplastic agents have been implicated as a cause of HVOD, but the disease is most commonly seen within 30 days after hematopoietic stem cell transplantation. The possible association between Mylotarg infusion and HVOD is discussed.

Original languageEnglish (US)
Pages (from-to)895-897
Number of pages3
JournalBone Marrow Transplantation
Volume28
Issue number9
DOIs
StatePublished - 2001

Fingerprint

Hepatic Veno-Occlusive Disease
Acute Myeloid Leukemia
Hematopoietic Stem Cell Transplantation
Antineoplastic Agents
Monoclonal Antibodies
gemtuzumab

Keywords

  • Acute myeloid leukemia
  • Hepatotoxicity
  • Mylotarg

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Development of hepatic veno-occlusive disease after mylotarg infusion for relapsed acute myeloid leukemia. / Tack, D. K.; Letendre, L.; Kamath, Patrick Sequeira; Tefferi, Ayalew.

In: Bone Marrow Transplantation, Vol. 28, No. 9, 2001, p. 895-897.

Research output: Contribution to journalArticle

@article{a1e7eaa0cb604668a674bb261e55823f,
title = "Development of hepatic veno-occlusive disease after mylotarg infusion for relapsed acute myeloid leukemia",
abstract = "Mylotarg (gemtuzumab zogamicin) is a conjugated monoclonal antibody that has recently become available for use in patients with relapsing or refractory acute myeloid leukemia. Reversible hepatotoxicity is common after administration. We describe the first report of hepatic veno-occlusive disease (HVOD) developing after Mylotarg infusion in a patient who underwent hematopoietic stem cell transplantation 8 months earlier. Certain antineoplastic agents have been implicated as a cause of HVOD, but the disease is most commonly seen within 30 days after hematopoietic stem cell transplantation. The possible association between Mylotarg infusion and HVOD is discussed.",
keywords = "Acute myeloid leukemia, Hepatotoxicity, Mylotarg",
author = "Tack, {D. K.} and L. Letendre and Kamath, {Patrick Sequeira} and Ayalew Tefferi",
year = "2001",
doi = "10.1038/sj.bmt.1703242",
language = "English (US)",
volume = "28",
pages = "895--897",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Development of hepatic veno-occlusive disease after mylotarg infusion for relapsed acute myeloid leukemia

AU - Tack, D. K.

AU - Letendre, L.

AU - Kamath, Patrick Sequeira

AU - Tefferi, Ayalew

PY - 2001

Y1 - 2001

N2 - Mylotarg (gemtuzumab zogamicin) is a conjugated monoclonal antibody that has recently become available for use in patients with relapsing or refractory acute myeloid leukemia. Reversible hepatotoxicity is common after administration. We describe the first report of hepatic veno-occlusive disease (HVOD) developing after Mylotarg infusion in a patient who underwent hematopoietic stem cell transplantation 8 months earlier. Certain antineoplastic agents have been implicated as a cause of HVOD, but the disease is most commonly seen within 30 days after hematopoietic stem cell transplantation. The possible association between Mylotarg infusion and HVOD is discussed.

AB - Mylotarg (gemtuzumab zogamicin) is a conjugated monoclonal antibody that has recently become available for use in patients with relapsing or refractory acute myeloid leukemia. Reversible hepatotoxicity is common after administration. We describe the first report of hepatic veno-occlusive disease (HVOD) developing after Mylotarg infusion in a patient who underwent hematopoietic stem cell transplantation 8 months earlier. Certain antineoplastic agents have been implicated as a cause of HVOD, but the disease is most commonly seen within 30 days after hematopoietic stem cell transplantation. The possible association between Mylotarg infusion and HVOD is discussed.

KW - Acute myeloid leukemia

KW - Hepatotoxicity

KW - Mylotarg

UR - http://www.scopus.com/inward/record.url?scp=0035202001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035202001&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1703242

DO - 10.1038/sj.bmt.1703242

M3 - Article

VL - 28

SP - 895

EP - 897

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -